Full text is available at the source.
The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
Retatrutide and the new approach using three hormones to treat obesity and related heart and metabolism problems
AI simplified
Abstract
Phase 2 trials report unprecedented weight reductions with retatrutide (LY3437943), a novel triple agonist targeting GLP-1, GIP, and glucagon receptors.
- Retatrutide may offer a new approach to obesity treatment beyond existing therapies.
- Weight loss observed with retatrutide is comparable to that achieved through bariatric surgery.
- The treatment could provide additional benefits for metabolic conditions like NASH and cardiovascular disease.
- This drug illustrates advancements in multi-agonist peptide design, potentially changing obesity pharmacotherapy.
AI simplified